Nutra Pharma Corp (NPHC) Accumulated Expenses (2010 - 2026)

Nutra Pharma has disclosed Accumulated Expenses across 17 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 9.37% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (up 9.37% YoY), while the FY2025 annual figure was $2.2 million, up 3.96% from the prior year.
• Accumulated Expenses came in at $2.3 million for Q2 2026 at Nutra Pharma, up from $2.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $2.3 million in Q2 2026 to a low of $1.1 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $1.9 million, with a median of $2.0 million recorded in 2024.
• The largest YoY upside for Accumulated Expenses was 59.25% in 2022 against a maximum downside of 26.01% in 2022.
• Over 5 years, Accumulated Expenses stood at $1.7 million in 2022, then increased by 13.26% to $1.9 million in 2023, then rose by 10.66% to $2.1 million in 2024, then grew by 3.96% to $2.2 million in 2025, then rose by 5.85% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.3 million in Q2 2026, $2.2 million in Q1 2026, and $2.2 million in Q4 2025.